Tom15 wrote:Someone very close to me was diagnosed with cancer and had previously been taking copaxone for two years. Nobody thought there was any connection. However, Teva seems very interested. Which is provoking this question. Has anyone else out there had a similar experience?
Glatiramer acetate was clastogenic in two separate in vitro chromosomal aberration assays in cultured human lymphocytes but not clastogenic in an in vivo mouse bone marrow micronucleus assay.
Female MS patients treated with glatiramer acetate showed an elevated rate of breast cancer and all MS patients treated with beta-interferons showed an elevated risk of non-breast cancers though not statistically significant (p = 0.122 and 0.072, respectively).
Further study is needed to assess possible associations between long-term exposure to the novel immunomodulatory treatments in MS and rate of cancer.
When considering all patients, treated patients had a 3-fold higher risk of developing cancer, if they had a history of IS (P = 0.0035).
For treated patients, the cancer sites were more likely the breast, the urinary tract, the digestive system and the skin.
CONCLUSION: Our data suggest that MS patients do not have an increased risk of cancer. Rather for several types of cancer a significantly reduced risk was observed, except for breast cancer in women treated with IS. The relative increased risk of breast cancer in MS women under IS treatment warrants further attention.
LR1234 wrote:Hi Tom,
1 in 3 people apparantly get cancer (according to the statistics) so I think the connection with copaxone is probably not a strong one If it was it would have become apparant in the trials.
Users browsing this forum: No registered users